Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Mind Medicine (MindMed) Inc. - Common Shares (NQ:MNMD)

13.39 UNCHANGED
Streaming Delayed Price Updated: 4:15 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mind Medicine (MindMed) Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
33 34 Next >
MindMed to Report Q3 2025 Financial Results on November 6, 2025
From Mind Medicine (MindMed) Inc.
Via Business Wire
Mind Medicine (MindMed) Inc. Announces Pricing of $225 Million Public Offering
From Mind Medicine (MindMed) Inc.
Via Business Wire
Mind Medicine (MindMed) Inc. Announces Proposed Public Offering
From Mind Medicine (MindMed) Inc.
Via Business Wire
Earnings Scheduled For July 31, 2025
 
Via Benzinga
MindMed Announces New Employee Inducement Grant
From Mind Medicine (MindMed) Inc.
Via Business Wire
Mind Medicine Analyst Cites Strong Phase 3 Pipeline For Anxiety, Depression
Needham starts MindMed at Buy with a $28 target, citing strong Phase 3 prospects for MM120 in anxiety and depression and solid cash position. 
Via Benzinga
The Insider Report: Panic Never Pays
 
Via Benzinga
MindMed Announces New Employee Inducement Grants
From Mind Medicine Inc.
Via Business Wire
New MindMed Retrospective Study Presented at Psych Congress 2025 Reveals High Rates of Suicidal Ideation (SI) in Adults with Generalized Anxiety Disorder (GAD)
From Mind Medicine (MindMed) Inc.
Via Business Wire
MindMed Announces New Employee Inducement Grants
From Mind Medicine Inc.
Via Business Wire
Journal of the American Medical Association (JAMA) Publishes Results from First-Ever Randomized, Placebo-Controlled Clinical Trial Assessing the Dose-Dependent Efficacy of MM120 (Lysergide D-Tartrate, LSD) in Generalized Anxiety Disorder (GAD)
From Mind Medicine Inc.
Via Business Wire
MindMed to Participate in September Investor Conferences
From Mind Medicine Inc.
Via Business Wire
If You'd Invested $1,000 in Mind Medicine (MNMD) Stock 5 Years Ago, Here's How Much You'd Have Today
Mind Medicine stock hasn't beaten the market over the last five years, but what comes next? 
Via The Motley Fool
MindMed Announces New Employee Inducement Grants
From Mind Medicine Inc.
Via Business Wire
MindMed (MNMD) Q2 2025 Earnings Call Transcript
Via The Motley Fool
Topics Earnings Initial Public Offering
MindMed Reports Strong Q2 2025 Results
Via The Motley Fool
1 Reason to Buy MindMed (MNMD)
The U.S. public and the nation's politicians seem to be coming around to the idea of reforming psychedelic drug laws. Looser restrictions on research would help this company. 
Via The Motley Fool
Topics Cannabis Law Enforcement
MindMed (MNMD) Q2 Net Loss Jumps 625%
Via The Motley Fool
Topics Intellectual Property
MindMed Reports Q2 2025 Financial Results and Business Updates
From Mind Medicine Inc.
Via Business Wire
MindMed to Report Second Quarter 2025 Financial Results on July 31, 2025
From Mind Medicine (MindMed) Inc.
Via Business Wire
MindMed Announces New Employee Inducement Grants
From Mind Medicine (MindMed) Inc.
Via Business Wire
MindMed Announces New Employee Inducement Grants
From Mind Medicine Inc.
Via Business Wire
Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032
From FN Media Group LLC
Via GlobeNewswire
Why Mind Medicine Gave Investors a Powerful Buzz in May
Via The Motley Fool
Topics Law Enforcement
Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032
EQNX::TICKER_START (NYSE:CYBN),(NEO:CYBN),(NASDAQ:CMPS),(NASDAQ:SAGE),(NASDAQ:MNMD),(NASDAQ:ATAI),(NEO:MMED) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
MindMed to Participate in June Investor Conferences
From Mind Medicine Inc.
Via Business Wire
MindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial Officer
From Mind Medicine Inc.
Via Business Wire
Ex-Gov't Foe Joins Trump, RFK Jr.'s HHS To Lead Psychedelics Policy: What It Means For Investors
Psychedelics litigator Matthew Zorn joins HHS under RFK Jr. to lead policy. What it means for CMPS, MNMD, CYBN, PSIL & more. 
Via Benzinga
Topics Government
Why Mind Medicine Stock Vaulted More Than 8% Higher Today
Via The Motley Fool
Let's uncover which stocks are experiencing notable gaps during today's session.
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Tuesday. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
33 34 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.